Company intelligence / Profile preview
Neowise Biotechnology
Suzhou, Jiangsu, Chinaneowisebio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Neowise has advanced several TCR-T cell therapy programs into clinical trials for solid tumors. Positive efficacy and favorable safety profiles have been observed in multiple indications including colorectal, pancreatic, and ovarian cancers. The company’s proprietary CAST® platform enables rapid discovery of high-affinity natural TCRs targeting a wide range of tumor antigens.
- Therapeutic areas
- Oncology
- Modalities
- TCR-T cell therapyCell therapyGene therapy (as part of TCR-T platform)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
BeOne Medicines Ltd. — licensing agreement for use of Neowise’s proprietary antigen-specific TCR molecules to develop iPSC-based off-the-shelf cell therapies.
Beyond the preview
Go deeper on Neowise Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neowise Biotechnology.